Blue Sky CANNABIS TECHNOLOGIES (CSE:C.CAN, Stock Forum): This play is so simple it’s scary – take existing pharmaceutical therapies, rip them apart to figure out what’s the active ingredients are in same, figure out which of those ingredients are also found in cannabinoids, and lay down some IP on those cannabinoid therapies. GW Pharma is doing it the traditional way, with five years plus of trials before a product will be ready for market. C.CAN is fast-tracking it and has already cranked out glaucoma and arthritis IP in just a few months. Those ‘big brains’ I have been long talking about as being part of Affinor’s dream team roster? They’re principals in this one. I see it as very undervalued, and expect there to be a WiLan like vault of potentially profitable IP at the company by year’s end.